News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Innomed Technologies, Inc Adds Viasys To Patent Lawsuit


10/19/2005 5:10:31 PM

BOCA RATON, Fla.--(BUSINESS WIRE)--March 18, 2004--InnoMed Technologies announced today that the United States District Court in Orlando, Florida has determined that it has jurisdiction over Innomed's claims for patent infringement against the manufacturer of the Spiritus nasal interface, Worldwide Medical Technologies, Inc. InnoMed has sued Worldwide and its former distributor, Viasys Healthcare, Inc., (VAS-NYSE) for the infringement of U.S. Patent 6,595, 215. The patent is directed, among other things, to a ventilation interface for sleep apnea therapy. The interface includes a pair of nasal inserts adapted to form a seal against the nares of a patient's nose.

"The Court's ruling on jurisdiction has now cleared the way to proceed forward on our suit to protect Innomed's Nasal-Aire products from infringement", said Shara Hernandez, President of InnoMed Technologies, Inc. "We have a number of issued patents and patents pending," Ms. Hernandez stated, "and we intend to protect our intellectual property rights in our new CPAP devices."

InnoMed designs, manufacturers and markets the innovative Nasal-Aire (R), Nasal-Aire (R) II and the Nasal-Aire II Critical Care devices.

InnoMed Technologies, Inc., is a research-oriented, privately held, 21st Century medical technologies company. The company is poised to bring new and more effective medical products and devices to the public through a medical development and engineering team, as well as acquisitions of other medical related companies. InnoMed holds several patents and has several patents pending. More information regarding InnoMed Technologies is available at http://www.innomedinc.com.

A Private Securities Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain information included in this press release (as well as information included in written statements to be made) contain statements that are forward-looking, such as those relating to consummation of the transaction, anticipated future revenue of the Company, and success of current public offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward looking statements.

Contact:

InnoMed Technologies, Inc., Boca Raton Elizabeth Kelley Grace, 561/989-9855 lizkgrace@aol.com

Source: InnoMed Technologies


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES